We are live on ! Find out more
CRVS icon

Corvus Pharmaceuticals
CRVS

164 hedge funds and large institutions have $1.02B invested in Corvus Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 55 increasing their positions, 30 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

185% more capital invested

Capital invested by funds: $359M → $1.02B (+$665M)

172% more first-time investments, than exits

New positions opened: 68 | Existing positions closed: 25

158% more call options, than puts

Call options by funds: $21M | Put options by funds: $8.14M

83% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 30

32% more funds holding

Funds holding: 124 → 164 (+40)

20.94% more ownership

Funds ownership: 62.51% → 83.45% (+21%)

Holders
164
Holders Change
+40
Holders Change %
+32.26%
% of All Funds
2.02%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.06%
New
68
Increased
55
Reduced
30
Closed
25
Calls
$21M
Puts
$8.14M
Net Calls
+$12.9M
Net Calls Change
+$13.2M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$46M
2
DTC
Deep Track Capital
Connecticut
+$39.8M
3
CC
Commodore Capital
New York
+$36M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$32M
5
B
Braidwell
Connecticut
+$28M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$22.1M
2
Morgan Stanley
Morgan Stanley
New York
-$17.1M
3
MB
MPM BioImpact
Massachusetts
-$17.1M
4
ACM
ADAR1 Capital Management
Texas
-$6.03M
5
Jane Street
Jane Street
New York
-$5.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
DA
26
DCF Advisers
Connecticut
$9.33M -$1.46M -91,500 -13%
EAM
27
Eventide Asset Management
Massachusetts
$8.05M +$8.78M +550,000 New
Marshall Wace
28
Marshall Wace
United Kingdom
$8.02M +$5.3M +332,037 +154%
BOCH
29
Blue Owl Capital Holdings
New York
$7.97M +$8.7M +545,000 New
Two Sigma Investments
30
Two Sigma Investments
New York
$7.9M +$6.32M +396,271 +276%
Northern Trust
31
Northern Trust
Illinois
$7.4M +$1.22M +76,333 +18%
VFT
32
Vanguard Fiduciary Trust
Pennsylvania
$7.38M +$8.05M +504,631 New
EMFAT
33
Emerald Mutual Fund Advisers Trust
Pennsylvania
$6.72M +$7.33M +459,253 New
LGM
34
Logos Global Management
California
$6.58M -$798K -50,000 -10%
NI
35
Nextech Invest
Switzerland
$6.58M +$7.18M +450,000 New
RCM
36
RA Capital Management
Massachusetts
$6.58M +$7.18M +450,000 New
Citadel Advisors
37
Citadel Advisors
Florida
$6.47M +$3.74M +234,340 +113%
UBS Group
38
UBS Group
Switzerland
$4.23M +$1.23M +77,108 +36%
Voloridge Investment Management
39
Voloridge Investment Management
Florida
$4.07M +$4.44M +278,007 New
SFM
40
Sphera Funds Management
Israel
$3.63M -$2.55M -159,748 -39%
DP
41
Diadema Partners
New Jersey
$3.58M +$3.91M +244,811 New
Barclays
42
Barclays
United Kingdom
$3.57M -$2.41M -150,990 -38%
Bank of America
43
Bank of America
North Carolina
$3.47M +$8.12K +509 +0.2%
APM
44
Avidity Partners Management
Texas
$3.43M +$3.67M +230,000 New
SSC
45
Spruce Street Capital
New York
$3.39M +$3.7M +231,585 New
SAM
46
SEB Asset Management
$3.32M +$3.62M +226,837 New
Charles Schwab
47
Charles Schwab
California
$2.75M +$271K +16,956 +10%
Bank of New York Mellon
48
Bank of New York Mellon
New York
$2.71M +$857K +53,719 +41%
PCMH
49
Polymer Capital Management (HK)
Hong Kong
$2.68M +$2.92M +183,187 New
BHCM
50
Brevan Howard Capital Management
Jersey
$2.46M +$2.68M +167,971 New
1
2
3 4 5

CRVS Hedge Fund Activity: Q1 2026 in Review

164 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q1 2026, worth a combined $1.02B — up 185% from $359M a quarter earlier.

Buyers outnumbered sellers: 68 funds opened new CRVS positions and 25 closed out — a net gain of 43 holders — while 55 added to existing stakes and 30 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $46M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $22.1M sold.

  • 164 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q1 2026, up from 124 in Q4 2025.
  • Funds reported $1.02B of Corvus Pharmaceuticals stock for Q1 2026, up 185% quarter-over-quarter.
  • 68 funds opened new Corvus Pharmaceuticals positions in Q1 2026 and 25 closed out, a net change of +43 holders.
  • The largest Corvus Pharmaceuticals buyer in Q1 2026 was T. Rowe Price Associates, an estimated $46M added.
  • The largest Corvus Pharmaceuticals seller in Q1 2026 was Point72 Asset Management, an estimated $22.1M sold.

Based on aggregated 13F filings for Q1 2026.